Three disease-modifying therapies (DMTs)—EMD Serono’s Mavenclad, Novartis’s Mayzent, and Biogen’s Vumerity—joined the crowded U.S. multiple sclerosis (MS) market just in the past year. Several more are nearing launch, including BMS’s Zeposia and Novartis’s ofatumumab, sustaining a rapid pace of change in the MS market. Developers of both current and emerging DMTs must continually reassess their products’ level of differentiation and likely future role in this continually evolving and highly competitive space. This report will explore neurologists’ perceptions of established and newly launched DMTs, their prescribing habits in today’s market, and anticipated changes in brand usage as more DMTs expand—and further complicate—prescribers’ choice.
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets Covered: United States
Primary research: Survey of 94 U.S. neurologists
Key drugs covered: Aubagio, glatiramer acetate, Gilenya, interferons, Lemtrada, Mavenclad, Mayzent, Ocrevus, ofatumumab, Tecfidera, Tysabri, Vumerity, Zeposia
Key companies: Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Novartis, Roche, Sanofi Genzyme
Key insights provided: